POSLUMA

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   May 25, 2023

   3 yr 1 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   May 25, 2028

   in 2 yr

4. Patent 12390540 expires

   Listed drug substance patent expiration.

   Aug 23, 2038

   in 12 yr 4 mo

5. Patent 11413360 expires

   Listed drug substance patent expiration.

   Nov 22, 2038

   in 12 yr 7 mo

6. Patent 11413360 expires

   Listed drug substance patent expiration.

   Nov 22, 2038

   in 12 yr 7 mo

7. Patent 12357711 expires

   Listed drug substance patent expiration.

   Nov 22, 2038

   in 12 yr 7 mo

8. Patent 12377176 expires

   Listed drug substance patent expiration.

   Nov 22, 2038

   in 12 yr 7 mo

9. Patent 12036290 expires

   Listed drug product patent expiration.

   Nov 27, 2041

   in 15 yr 8 mo

10. Patent 12036290 expires

    Listed drug product patent expiration.

    Nov 27, 2041

    in 15 yr 8 mo

11. Patent 12427207 expires

    Listed drug product patent expiration.

    Nov 27, 2041

    in 15 yr 8 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

• NCENew chemical entity exclusivity (5 years)

  May 25, 2028

  in 2 yr

Listed patents (8)